肌层浸润性尿路癌新辅助化疗后残留病灶辅助化疗的发生率、模式与结局
基于回顾性国际尿路上皮癌研究数据库,474例接受新辅助化疗的患者中129例有不良残留病灶(≥ypT3和/或ypN+),其中106例监测、23例辅助化疗。辅助化疗组中位至复发时间18个月 vs 监测组10个月(p=0.06),多变量分析校正后复发风险显著降低(p=0.01);ypT4b/ypN+亚组辅助化疗中位至复发时间20 vs 9个月(HR 0.43,95%CI 0.21-0.89),总生存无差异。
要点
- 新辅助化疗后不良残留病灶患者中辅助化疗使用不普遍(23/129)。
- 辅助化疗组中位至复发时间18个月 vs 监测组10个月(p=0.06)。
- ypT4b/ypN+亚组辅助化疗中位至复发时间20 vs 9个月(HR 0.43,95%CI 0.21-0.89)。
核心结论
- 新辅助化疗后高危残留病灶患者中辅助化疗在临床实践中不常用,但可能降低复发风险。
- 需要进一步研究以确定该高危人群的最佳治疗并改善临床结局,如正在进行的辅助免疫治疗试验。
研究设计与样本
- 回顾性研究,来自国际尿路上皮癌研究数据库,共纳入474例接受新辅助化疗的患者,其中129例有不良残留病灶(≥ypT3和/或ypN+)。
- 129例中106例接受监测,23例接受辅助化疗。
主要发现
- 中位随访30个月,超过50%的患者出现复发,中位至复发时间为16个月(范围<1-108个月)。
- 辅助化疗组中位至复发时间18个月 vs 监测组10个月(p=0.06)。
- 多变量分析校正新辅助化疗类型、年龄和病理分期后,辅助化疗与复发风险显著降低相关(p=0.01)。
- ypT4b/ypN+亚组(辅助化疗19例,监测50例)中,辅助化疗组中位至复发时间20 vs 9个月(风险比0.43,95%CI 0.21-0.89)。
- 总生存方面未发现差异。
关键数值与推荐
- 辅助化疗和监测中最常用方案均为吉西他滨-顺铂(30.4%),大多数患者(82.6%)换用了不同方案。
临床怎么用
- 原文未据此给出推荐。
局限性
- 局限性包括回顾性设计。
- 需要进一步研究以确定该高危人群的最佳治疗并改善临床结局。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Patients with residual muscle-invasive urinary tract cancer after neoadjuvant chemotherapy (NAC) have a high risk of recurrence. OBJECTIVE: To retrospectively evaluate whether additional adjuvant chemotherapy (AC) improves outcomes compared with surveillance in patients with significant residual disease despite NAC. DESIGN, SETTING, AND PARTICIPANTS: We identified 474 patients who received NAC from the Retrospective International Study of Cancers of the Urothelium database, of whom 129 had adverse residual disease (≥ypT3 and/or ypN+). OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Time to relapse (TTR) was the primary endpoint assessed starting from 2mo after surgery to minimize immortal time bias. Secondary endpoints included overall survival (OS), incidence of AC use, and chemotherapy patterns. Kaplan-Meier and Cox regression models estimated TTR, OS, and associations with AC, adjusting for the type of NAC, age, and pathological stage in multivariable analyses. RESULTS AND LIMITATIONS: A total of 106 patients underwent surveillance, while 23 received AC. Gemcitabine-cisplatin was the most frequent regimen employed in both settings (30.4%), and the majority (82.6%) of the patients switched to a different regimen. Median follow-up was 30mo. Over 50% of patients developed a recurrence. Median TTR was 16mo (range: <1-108mo). Longer median TTR was observed with AC compared with surveillance (18 vs 10mo, p=0.06). Risk of relapse significantly decreased with AC when adjusted in multivariable analyses (p=0.01). The subgroup analyses of ypT4b/ypN+ patients (AC: 19; surveillance: 50) who received AC had significantly greater median TTR (20 vs 9mo; hazard ratio 0.43; 95% confidence interval: 0.21-0.89). No difference in OS was found. Limitations include the retrospective design. CONCLUSIONS: The utilization of AC after NAC in patients with high-risk residual disease is not frequent in clinical practice but might reduce the risk of recurrence. Further investigation is needed in this high-risk population to identify optimal therapy and to improve clinical outcomes such as the ongoing adjuvant immunotherapy trials. PATIENT SUMMARY: We found that administering additional chemotherapy in patients who had significant residual disease despite preoperative chemotherapy is not frequent in clinical practice. While it might reduce the risk of recurrence, it did not clearly increase overall survival. We encourage participation in the ongoing immunotherapy trials to see whether we can improve outcomes using a different type of therapy that stimulates the immune system.
引用
- Martinez Chanza N, Werner L, Plimack E, et al. Incidence, Patterns, and Outcomes with Adjuvant Chemotherapy for Residual Disease After Neoadjuvant Chemotherapy in Muscle-invasive Urinary Tract Cancers. Eur Urol Oncol. 2019. PMID: 31411990. doi:10.1016/j.euo.2018.12.013
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。